← All trials
NCT03168334
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 11, 2017
- Primary completion
- Jul 24, 2018
- Completion date
- Jul 24, 2018
- First posted
- May 30, 2017
- Last posted
- Apr 1, 2021
- Enrollment
- 801
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Bausch Health CompaniesLead sponsor
- Bausch Health CompaniesStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.